AXA/2025/FY/Earnings presentation: Difference between revisions
Content deleted Content added
PlumBot: publish from draft |
PlumBot: publish from draft |
||
Line 18:
=== Full Year 2025 earnings presentation ===
* '''
* '''Presentation date''': February 26, 2026 <sup>p. 1</sup>
=== Important legal information and cautionary statements concerning forward-looking statements and the use of non-GAAP financial measures ===
* '''Disclaimer''' regarding forward-looking statements, which are subject to known and unknown risks and uncertainties <sup>p. 2</sup>.
* '''Expected UEPS growth''' for 2026 is provided as one-off guidance in the context of the last year of the Group's current strategic plan <sup>p. 2</sup>.
* '''
* '''Non-GAAP measures''' and alternative performance measures (APMs) used include "Underlying earnings", UEPS ("underlying earnings per share"), "underlying return on equity", "combined ratio", and "debt gearing" <sup>p. 2</sup>.
* '''Financial statements''' for the year ended December 31, 2025 were examined by the Board of Directors on February 25, 2026, and are subject to completion of an audit procedure
=== Table of contents ===
Line 36 ⟶ 37:
== FY25 Highlights ==
* '''Section
=== Full Year 2025 | Excellent performance ===
<div style="overflow-x:auto">
{| class="wikitable
|+ Key financial highlights, FY25 <sup>p. 5</sup>
! style="text-align:left" | Metric
! class="col-
|-
| style="text-align:left" | Revenues
| class="col-s" style="text-align:right" | +6% vs. FY24
|-
| style="text-align:left" | Underlying EPS
| class="col-s" style="text-align:right" | +8% vs. FY24
|-
| style="text-align:left" | Return on equity
| class="col-s" style="text-align:right" | 16%
|-
| style="text-align:left" | Solvency II ratio
| class="col-s" style="text-align:right" | 224%
|-
| style="text-align:left" | Dividend per share
| class="col-s" style="text-align:right" | +8% growth
|-
| style="text-align:left" | Share buyback
| class="col-s" style="text-align:right" | EUR 1.25bn annual program
|-
| style="text-align:left" | Underlying EPS growth target for 2026
| class="col-s" style="text-align:right" | Upper end of 6% to 8%
|}
</div>
* '''Dividend per share''' +8% growth, based on the dividend proposed by AXA's Board of Directors on February 25, 2026, subject to approval by the Shareholders' Annual General Meeting on April 30, 2026 <sup>p. 5</sup>
Line 80 ⟶ 79:
! class="col-s" style="text-align:right" | FY24
! class="col-s" style="text-align:right" | FY25
! class="col-s" style="text-align:right" | Change
! class="col-s" style="text-align:right" | Change
|-
| style="text-align:left" | Underlying earnings
Line 90 ⟶ 89:
|}
</div>
* High organic growth: +6% top line growth, well balanced across lines (P&C: +5%, Life: +9%, Health: +5%) <sup>p. 6</sup>
* Record profitability: Further margin expansion in P&C and L&H; improvement in efficiency <sup>p. 6</sup>
* Scaling the business: Continued investments in growth and technology <sup>p. 6</sup>
* Consistent earnings growth while enhancing reserve prudence <sup>p. 6</sup>
=== Diversified franchise, well positioned in an attractive industry ===
Line 99:
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ FY25 gross written premium split (excluding AXA IM and holdings) <sup>p. 7</sup>
! style="text-align:left" | Segment
! class="col-s" style="text-align:right" | Share
Line 110:
|-
| style="text-align:left" | Large & Specialty
| style="text-align:right" | 17%
|-
| style="text-align:left" | SME & Mid-market
| style="text-align:right" | 16%
|-
| style="text-align:left" | Retail
| style="text-align:right" | 17%
|}
</div>
*
*
** Leading brand & high customer NPS <sup>p. 7</sup>
** Strong and diversified distribution <sup>p. 7</sup>
** Technical expertise to price & underwrite risks <sup>p. 7</sup>
** Scale offering cost advantage <sup>p. 7</sup>
=== Laying the foundation for the next plan ===
Line 136:
* '''Earnings growth outlook''' supported by these pillars, providing confidence in sustaining earnings growth <sup>p. 8</sup>
==
=== FY25 business performance ===
* '''Section 2''': FY25 Business Performance presented by Guillaume Borie, Global Head of Finance, Strategy, Underwriting, Risk, and Technology <sup>p. 9</sup>.
Line 173 ⟶ 175:
=== P&C | Strong margins, confidence in sustaining growth ===
*
* '''Underlying earnings''' +9% at constant FX to EUR 5.9bn <sup>p. 11</sup>.
* '''Retail and SME
** '''2025
** '''Beyond 2025
* '''AXA XL
** '''2025
** '''Beyond 2025
* '''Earnings
** Continued progress on efficiency <sup>p. 11</sup>.
** Higher investment income <sup>p. 11</sup>.
** Data
=== L&H | Good momentum, well positioned to capture growth opportunities ===
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ Financial highlights and strategic priorities <sup>p. 12</sup>
! style="text-align:left" | EUR billion
! class="col-s" style="text-align:right" | Value
|-
| style="text-align:left" | Gross written premiums (GWP)
| style="text-align:right" | 57
|-
| style="text-align:left" | Underlying earnings
| style="text-align:right" | 3.5
|}
</div>
* (donut) '''GWP mix''': Short-term and Long-term segments — shares not labeled.
* '''Long-term business''' strategic priorities:
** '''2025''': Accelerating net flows in Savings at attractive margins
** '''Beyond 2025''': Capturing savings & retirement opportunity, sourcing best asset management products for our customers
* '''Short-term business''' strategic priorities:
** '''2025''': Growing technical results while absorbing Mexico VAT impact
** '''Beyond 2025''': Capitalizing on demand for health & protection while further improving our margins
* '''Operational drivers''' supporting growth and efficiency:
** Focus on cost reduction
** Increasing penetration of Protection riders in Savings offerings
** Leveraging AI to reduce claims leakage & improve customer outcomes in Health
* '''Underlying earnings''' +7% at constant FX to EUR 3.5bn <sup>p. 12</sup>.
== Financial Performance ==
=== FY25
* '''Section 3''': FY25 Financial Performance presented by Alban de Mailly Nesle, Group CFO <sup>p. 13</sup>
Line 210 ⟶ 227:
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ P&C GWP
! style="text-align:left" | EUR billion unless otherwise mentioned
! class="col-s" style="text-align:right" | FY24
Line 239 ⟶ 256:
| style="text-align:right" | +2%
|-
| style="text-align:left; font-weight:bold" | Total
| style="text-align:right; font-weight:bold" | 56.5
| style="text-align:right; font-weight:bold" | 58.0
Line 247 ⟶ 264:
|}
</div>
*
*
*
*
=== P&C | Delivering further margin expansion while enhancing reserve prudence ===
Line 286 ⟶ 303:
|}
</div>
*
** Margin expansion in '''Commercial lines''' SME & mid-market business and '''Personal lines''' reflecting
** Stable '''AXA XL Insurance''' margins at attractive levels reflecting disciplined cycle management
*
* '''Nat Cat charges
*
* Taking advantage of a good year to enhance '''reserve prudence'''
=== P&C | Earnings growth from higher underwriting and financial result ===
Line 304 ⟶ 322:
| style="text-align:right" | 5,510
|-
| style="text-align:left" |
| style="text-align:right" | +292
|-
| style="text-align:left" |
| style="text-align:right" | +189
|-
| style="text-align:left" |
| style="text-align:right" | +435
|-
| style="text-align:left" |
| style="text-align:right" | -235
|-
Line 326 ⟶ 344:
|}
</div>
* Underlying earnings grew +9% at constant FX to EUR 5,872m (FY24: EUR 5,510m) <sup>p. 16</sup>.
* Underwriting result (includes expenses) driven by volume growth (+EUR 292m) and margin improvement (+EUR 189m) <sup>p. 16</sup>.
* Financial result driven by investment income (+EUR 435m) and partly offset by insurance finance expenses (-EUR 235m) <sup>p. 16</sup>.
* Underwriting result improved from strong volume growth and improved all-year combined ratio while enhancing reserve prudence <sup>p. 16</sup>.
* Investment income increased reflecting higher volumes and better reinvestment yields on fixed income assets <sup>p. 16</sup>.
* Insurance finance expenses
* Forex impact was unfavorable
=== Life & Health | Strong growth in premiums, positive net flows ===
Line 336 ⟶ 356:
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ Life GWP & Other Revenues
! style="text-align:left" | EUR billion unless otherwise mentioned
! class="col-s" style="text-align:right" | FY24
! class="col-s" style="text-align:right" | FY25
! class="col-s" style="text-align:right" | LFL Change
|-
| style="text-align:left" | Protection
Line 367 ⟶ 382:
| style="text-align:right" | -7%
|-
| style="text-align:left; font-weight:bold" |
| style="text-align:right; font-weight:bold" |
| style="text-align:right; font-weight:bold" |
| style="text-align:right; font-weight:bold" | +
|}
</div>
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ Health GWP & Other Revenues mix, FY24 vs FY25 <sup>p. 17</sup>
! style="text-align:left" | EUR billion
! class="col-s" style="text-align:right" | FY24
! class="col-s" style="text-align:right" | FY25
! class="col-s" style="text-align:right" | LFL Change
|-
| style="text-align:left" | Individual
Line 382 ⟶ 407:
| style="text-align:right" | +4%
|-
| style="text-align:left; font-weight:bold" |
| style="text-align:right; font-weight:bold" |
| style="text-align:right; font-weight:bold" |
| style="text-align:right; font-weight:bold" | +
|
</div>
{| class="wikitable fintable"
|+ Net flows by segment <sup>p. 17</sup>
! style="text-align:left" | EUR billion
! class="col-s" style="text-align:right" | Net flows
|-
| style="text-align:left" | Protection
| style="text-align:right" |
|-
| style="text-align:left" | Health
| style="text-align:right" |
|-
| style="text-align:left" | Unit-Linked
| style="text-align:right" |
|-
| style="text-align:left" | Capital light G/A
| style="text-align:right" |
|-
| style="text-align:left" | Traditional G/A
| style="text-align:right" | -5.0
|}
</div>
* Employee Benefits GWP and other revenues (including both short-term and long-term) was EUR 12.9bn (+4% vs. FY24) <sup>p. 17</sup>
* Net flows reached +EUR 5.4bn (vs. +EUR 1.5bn in FY24) <sup>p. 17</sup>
=== Life & Health | Strong volume growth in Savings and Protection impacted by higher interest rates on discounting ===
Line 423 ⟶ 443:
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ PVEP
! style="text-align:left" | EUR billion unless otherwise mentioned
! class="col-s" style="text-align:right" | FY24
! class="col-s" style="text-align:right" | FY25
! class="col-s" style="text-align:right" | LFL Change
|-
| style="text-align:left" | Protection & Health
Line 454 ⟶ 469:
| style="text-align:right" | -10%
|-
| style="text-align:left; font-weight:bold" |
| style="text-align:right; font-weight:bold" |
| style="text-align:right; font-weight:bold" |
| style="text-align:right; font-weight:bold" |
|}
</div>
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ NB CSM (pre-tax) and NBV (post-tax), FY24 vs FY25 <sup>p. 18</sup>
! style="text-align:left" | EUR billion
! class="col-s" style="text-align:right" | NB CSM (pre-tax)
! class="col-s" style="text-align:right" | NBV (post-tax)
|-
| style="text-align:left" |
| style="text-align:right" | 2.2
| style="text-align:right" | 2.3
|-
| style="text-align:left" | FY25
| style="text-align:right" | 2.2
| style="text-align:right" | 2.2
|-
| style="text-align:left" | LFL Change
| style="text-align:right" | +3%
| style="text-align:right" | stable
|}
</div>
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ NBV margin, FY24 vs FY25 <sup>p. 18</sup>
! style="text-align:left" | —
! class="col-s" style="text-align:right" | FY24
! class="col-s" style="text-align:right" | FY25
|-
| style="text-align:left" |
| style="text-align:right" | 4.4%
| style="text-align:right" | 4.5%
|}
</div>
* PVEP impacted by higher interest rates on discounting despite strong growth in Life volumes <sup>p. 18</sup>
*
* NBV broadly stable as strong growth in NB CSM balanced lower contribution from short-term multinational business in France <sup>p. 18</sup>
=== Life & Health | Growth in new business driving Normalized CSM growth ===
Line 481 ⟶ 519:
|+ Contractual Service Margin rollforward, FY24 to FY25 <sup>p. 19</sup>
! style="text-align:left" | EUR billion
! class="col-s" style="text-align:right" |
|-
| style="text-align:left" | FY24
Line 509 ⟶ 547:
</div>
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ Contractual Service Margin by segment <sup>p. 19</sup>
! style="text-align:left" | EUR billion
! class="col-s" style="text-align:right" | FY24
! class="col-s" style="text-align:right" | FY25
|-
| style="text-align:right" | 25.8
| style="text-align:right" | 25.4
|-
| style="text-align:left" | Health segment
| style="text-align:right" | 7.7
| style="text-align:right" | 7.6
|}
</div>
* '''Normalized CSM''' up by +2% LFL, with CSM release growth reflecting better margins and new business CSM growth impacted by higher rates <sup>p. 19</sup>.
* '''Economic variance''' reflecting government spreads tightening and positive equity market returns <sup>p. 19</sup>.
* '''Operating variance''' driven by better margins and net flows that were more than offset by a reduction in the duration of Group Life business in Switzerland <sup>p. 19</sup>.
* '''FX impact''' mainly from JPY and HKD depreciation <sup>p. 19</sup>.
* '''Normalized CSM growth''' +2% (comprising New business CSM, Underlying return on in-force, and CSM release) <sup>p. 19</sup>
=== Life & Health | Strong momentum in both short-term and long-term business ===
Line 524 ⟶ 575:
{| class="wikitable fintable"
|+ Underlying earnings bridge, FY24 to FY25 <sup>p. 20</sup>
! style="text-align:left" | EUR million unless otherwise mentioned
! class="col-s" style="text-align:right" | Underlying earnings
|-
Line 544 ⟶ 595:
| style="text-align:left" | FY25
| style="text-align:right" | 3,501
|}
</div>
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ Underlying earnings components <sup>p. 20</sup>
! style="text-align:left" | EUR million
! class="col-s" style="text-align:right" | FY24
! class="col-s" style="text-align:right" | FY25
|-
| style="text-align:left" | Short-term technical margin
| style="text-align:right" | 415
| style="text-align:right" | 479
|-
| style="text-align:left" | Long-term result incl. CSM release
| style="text-align:right" | 2,680
| style="text-align:right" | 2,804
|-
| style="text-align:left" | Financial result
| style="text-align:right" | 975
| style="text-align:right" | 946
|-
| style="text-align:left" | Tax & others
| style="text-align:right" | -748
| style="text-align:right" | -728
|}
</div>
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ Underlying earnings by segment <sup>p. 20</sup>
! style="text-align:left" | EUR billion
! class="col-s" style="text-align:right" | FY24
! class="col-s" style="text-align:right" | FY25
! class="col-s" style="text-align:right" | Change
|-
| style="text-align:left" | Life
| style="text-align:right" | 2.6
| style="text-align:right" | 2.7
| style="text-align:right" | +4%
|-
| style="text-align:left" | Health
| style="text-align:right" | 0.7
| style="text-align:right" | 0.8
| style="text-align:right" | +17%
|}
</div>
* '''Underlying earnings''' +7% LFL to EUR 3,501m <sup>p. 20</sup>
* Strong '''
* Higher '''
=== Growth in net income reflecting higher earnings & the gain from the sale of AXA IM ===
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ Earnings and net income
! style="text-align:left" | —
! class="col-s" style="text-align:right" | FY24
Line 592 ⟶ 677:
| style="text-align:right" | -
|-
| style="text-align:left" |
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" |
|-
| style="text-align:left" | Non-financial flows
Line 602 ⟶ 687:
| style="text-align:right" | —
|-
| style="text-align:left; padding-left:1.5em" |
| style="text-align:right" | -
| style="text-align:right" | +2.2
Line 612 ⟶ 697:
| style="text-align:right" | —
|-
| style="text-align:left" |
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" |
|}
</div>
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ Underlying earnings per share (reported basis) <sup>p. 21</sup>
! style="text-align:left" | EUR
! class="col-s" style="text-align:right" | FY24
! class="col-s" style="text-align:right" | FY25
! class="col-s" style="text-align:right" | Change
|-
| style="text-align:left" | Underlying earnings per share
| style="text-align:right" | 3.59
| style="text-align:right" | 3.86
| style="text-align:right" | +8%
|}
</div>
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ Underlying earnings per share change drivers <sup>p. 21</sup>
! style="text-align:left" | Driver
! class="col-s" style="text-align:right" | Contribution
|-
| style="text-align:left" | Earnings growth
| style="text-align:right" | +6%
|-
| style="text-align:left" | Capital management
| style="text-align:right" | +3%
|-
| style="text-align:left" | Forex
| style="text-align:right" | -2%
|-
| style="text-align:left" | AXA IM sale impact
| style="text-align:right" | -1%
|}
</div>
*
**
**
* '''Net income''' drivers:
**
** Lower financial flows reflecting unfavorable forex impact <sup>p. 21</sup>
=== Shareholders'
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ Shareholders' equity
! style="text-align:left" | EUR billion unless otherwise mentioned
! class="col-s" style="text-align:right" | FY24
Line 635 ⟶ 756:
! class="col-s" style="text-align:right" | FY25
|-
| style="text-align:left" | Shareholders' equity (
| style="text-align:right" | 49.9
| style="text-align:right" | 45.5
Line 715 ⟶ 836:
|}
</div>
* '''Reporting currency''' is in Euro billion <sup>p. 22</sup>.
Line 722 ⟶ 842:
* '''Net cash remittance''' increased to EUR 7.5bn in FY25 <sup>p. 23</sup>
** (bar) '''Net cash remittance trend''': FY24 EUR 7.7bn (comprising EUR 7.1bn ordinary remittance and EUR 0.6bn proceeds related to L&S reinsurance in-force treaties at AXA France and AXA Life Europe) → FY25 EUR 7.5bn <sup>p. 23</sup>
** '''Remittance ratio''' remained stable at 82% in FY24 and 82%
<div style="overflow-x:auto">
Line 762 ⟶ 882:
|+ Solvency II walk, FY24 to FY25 <sup>p. 24</sup>
! style="text-align:left" | EUR billion unless otherwise mentioned
! class="col-s" style="text-align:right" |
! class="col-s" style="text-align:right" |
! class="col-s" style="text-align:right" | Solvency II ratio (pts)
|-
Line 807 ⟶ 927:
|}
</div>
* Dividend & annual share buyback includes foreseeable dividends of -EUR 4.8bn and provision for annual share buyback for 2026 of -EUR 1.25bn <sup>p. 24</sup>.
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ Key sensitivities of Solvency II
! style="text-align:left" | Sensitivity
! class="col-s" style="text-align:right" | Impact (pts)
|-
| style="text-align:left" | Interest rate +50bps
Line 846 ⟶ 968:
</div>
*
* Euro sovereign spreads sensitivity assumes a 50bps spread widening of the Euro sovereign bonds vs. the Euro swap curve, applied on sovereign and quasi-sovereign exposures <sup>p. 24</sup>.
* Credit rating migration sensitivity assumes 20% of corporate bonds (including private debt) held are downgraded by one full letter (3 notches) <sup>p. 24</sup>.
=== Solvency II -impact of the end of grandfathering period and Solvency II revision ===
Line 856 ⟶ 976:
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ Solvency II ratio
! style="text-align:left" | Solvency II ratio
! class="col-m" style="text-align:right" | Value
Line 870 ⟶ 990:
|}
</div>
* EUR 2.4bn grandfathered debt is no longer eligible as capital from January 1, 2026 <sup>p. 25</sup>.
* Estimated based on the Solvency Capital Requirement (SCR) and the amount of capital (EOF) under Solvency II as of January 1, 2026, as if the Solvency II revision had come into force on the same date <sup>p. 25</sup>.
Line 884 ⟶ 1,005:
* '''Business performance''' shows all businesses in excellent shape, delivering strong growth and profitability <sup>p. 27</sup>.
* '''Diversified franchise''' is well-positioned to capture future growth opportunities <sup>p. 27</sup>.
* '''
=== February 26, 2026 Q&A Full Year 2025 earnings ===
* '''Session title''': Q&A Full Year 2025 Earnings
* '''Date''': February 26, 2026 <sup>p. 28</sup>
=== AXA Investor Relations | Keep in touch ===
* '''Investor Relations contact'''
* '''Follow us'''
<div style="overflow-x:auto">
{| class="wikitable"
|+ Meet our management event
! style="text-align:left" | Date
! class="col-m" style="text-align:right" | Event
Line 930 ⟶ 1,052:
== Appendices ==
* Section divider slide for the '''Appendices''' <sup>p. 30</sup>.
=== Table of contents ===
Line 941 ⟶ 1,063:
=== Gross financial debt and maturity breakdown as of December 31st, 2025 ===
* (stacked bar) '''Gross financial debt''':
** '''FY24''': EUR 19.2bn total; Tier 1 EUR 4.8bn, Tier 2 EUR 10.8bn, Senior debt EUR 3.5bn; debt gearing at 20.6% <sup>p. 32</sup>
** '''
** '''Jan 1st 2026''' (End of the grandfathering period): EUR 20.3bn total; Tier 1 EUR 3.2bn, Tier 2 EUR 11.3bn, Senior debt EUR 5.8bn (of which EUR 0.4bn redeemed in Jan 2026) <sup>p. 32</sup>
* (stacked bar) '''Contractual maturity breakdown''':
Line 950 ⟶ 1,071:
** '''2030''': Tier 2 EUR 0.7bn, Senior debt EUR 0.9bn <sup>p. 32</sup>
** '''2031-2039''': Senior debt EUR 1.5bn <sup>p. 32</sup>
** '''
** '''Undated''': Tier 1 EUR 4.6bn, Tier 2 EUR 0.7bn <sup>p. 32</sup>
** '''Of which grandfathered debt''': Tier 1 Undated EUR 1.4bn; Tier 2 2030 EUR 0.7bn, ≥2040 EUR 0.2bn <sup>p. 32</sup>
* (stacked bar) '''Economic maturity breakdown''':
** '''2026''': Tier 1 EUR 0.1bn <sup>p. 32</sup>
Line 962 ⟶ 1,081:
** '''2030''': Tier 2 EUR 0.7bn, Senior debt EUR 0.9bn <sup>p. 32</sup>
** '''2031-2039''': Tier 1 EUR 0.4bn, Tier 2 EUR 6.4bn, Senior debt EUR 1.5bn <sup>p. 32</sup>
** '''
** '''Undated''': Tier 1 EUR 4.0bn, Tier 2 EUR 0.7bn <sup>p. 32</sup>
** '''Of which grandfathered debt''': Tier 1 2026 EUR 0.1bn, 2028 EUR 0.1bn, 2031-2039 EUR 0.4bn, Undated EUR 0.8bn; Tier 2 2030 EUR 0.7bn, ≥2040 EUR 0.2bn <sup>p. 32</sup>
* '''Economic maturity''' accounts for the first date of step-up calls on institutionally placed subordinated debt; Solvency II RT1 debt with no step-up retains its undated nature <sup>p. 32</sup>
=== General
* '''Total General Account''' invested assets stood at EUR 450bn for FY25 <sup>p. 33</sup>.
* '''Duration gap''' was at -0.4 year <sup>p. 33</sup>.
* (donut) '''FY25 Total General Account invested assets''':
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ Invested assets (100%) in
! style="text-align:left" | Invested assets (100%) In EUR billion unless otherwise mentioned
! class="col-s" style="text-align:right" | FY25
Line 1,029 ⟶ 1,146:
</div>
* '''Other fixed income''' includes Asset Backed Securities (EUR 25bn), Residential Loans (EUR 16bn), Commercial & Agricultural Loans (EUR 7bn), and Agency Pools (EUR 8bn) <sup>p. 33</sup>.
* '''Listed equities''' includes hedges; listed equities excluding hedges stood at EUR 14bn <sup>p. 33</sup>.
* '''Private equity and hedge funds''' includes Private Equity (EUR 17bn), Hedge Funds (EUR 5bn), and Non-listed Equities (EUR 1bn) <sup>p. 33</sup>.
=== Structured and
<div style="overflow-x:auto">
Line 1,082 ⟶ 1,199:
* '''General Account''' (G/A) refers to General Account <sup>p. 34</sup>.
=== Investment portfolio | Fixed
<div style="overflow-x:auto">
{| class="wikitable fintable"
! style="text-align:left" | Asset mix
! class="col-s" style="text-align:right" | Share
|-
| style="text-align:left" | Government bonds & related
| style="text-align:right" | 32%
|-
| style="text-align:left" | Investment grade credit
| style="text-align:right" | 40%
|-
| style="text-align:left" | ABS/CLO/IG fund financing
| style="text-align:right" | 21%
|-
| style="text-align:left" | Below investment grade credit
| style="text-align:right" | 7%
|}
</div>
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ FY25 Fixed income reinvestment yield <sup>p. 35</sup>
! style="text-align:left" | Fixed income type
! class="col-s" style="text-align:right" | Yield
|-
| style="text-align:left" | Public fixed income
| style="text-align:right" | 3.5%
|-
| style="text-align:left" | Private & Structured fixed income
| style="text-align:right" | 4.7%
|-
| style="text-align:left; font-weight:bold" | Total fixed income
| style="text-align:right; font-weight:bold" | 3.9%
|}
</div>
* Fixed income reinvestment totaled EUR 57bn in FY25
* Government bonds & related: average rating: AA
* Investment grade credit: average rating: A
* Reinvestment yield achieved at 3.9% on EUR 57bn invested
* Average duration of 9 years
* Includes EUR 19.7bn of Private & Structured Credit invested at 4.7% (comprising CLOs, ABS, Infra & CRE debt, Fund financing and Private HY)
* Asset allocation reflects a gradual shift from alternative total return assets to Private & Structured credit
=== Table of contents ===
Line 1,105 ⟶ 1,251:
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ FY25 GWP
! style="text-align:left" | USD billion unless otherwise mentioned
! class="col-s" style="text-align:right" |
|-
| style="text-align:left" |
| style="text-align:right" | 35%
|-
| style="text-align:left" | Property
| style="text-align:right" | 29%
|-
| style="text-align:left" | Specialty
| style="text-align:right" | 19%
|-
| style="text-align:left" | Professional lines (including Cyber)
| style="text-align:right" | 17%
|}
</div>
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ FY25 GWP by geography <sup>p. 37</sup>
! style="text-align:left" | USD billion
! class="col-s" style="text-align:right" | Share
|-
| style="text-align:left" | Americas
| style="text-align:right" | 46%
|-
| style="text-align:left" | Europe & APAC
| style="text-align:right" | 35%
|-
| style="text-align:left" | UK & Lloyds
| style="text-align:right" | 19%
|}
</div>
* '''Business diversification''' is well balanced across lines of business and geographies <sup>p. 37</sup>
* '''Market leadership''' positions AXA XL in the top 3 globally for <sup>p. 37</sup>:
** Multinational Programs <sup>p. 37</sup>
Line 1,142 ⟶ 1,294:
** (bubble chart) '''Profitability vs Ex-price growth (%)''': shows relative positioning of key lines <sup>p. 37</sup>:
*** '''Property''': high profitability, high ex-price growth <sup>p. 37</sup>
*** '''Specialty''': moderate-to-high profitability, moderate ex-price growth <sup>p. 37</sup>
*** '''Casualty''': moderate profitability, moderate ex-price growth <sup>p. 37</sup>
*** '''Professional lines''': lower profitability, lower ex-price growth <sup>p. 37</sup>
=== P&C | Focus on
<div style="overflow-x:auto">
Line 1,162 ⟶ 1,314:
|-
| style="text-align:left" | Claims reserves ratio (IFRS4 basis)
| style="text-align:right" | 179
| style="text-align:right" | 185
| style="text-align:right" | 193
| style="text-align:right" | 188
| style="text-align:right" | 189
| style="text-align:right" | —
| style="text-align:right" | —
Line 1,176 ⟶ 1,328:
| style="text-align:right" | —
| style="text-align:right" | —
| style="text-align:right" | 198
| style="text-align:right" | 195
| style="text-align:right" | 180
| style="text-align:right" | 175
|-
| style="text-align:left" | Technical reserves ratio (IFRS4 basis)
| style="text-align:right" | 213
| style="text-align:right" | 227
| style="text-align:right" | 233
| style="text-align:right" | 226
| style="text-align:right" | 227
| style="text-align:right" | —
| style="text-align:right" | —
Line 1,196 ⟶ 1,348:
| style="text-align:right" | —
| style="text-align:right" | —
| style="text-align:right" | 234
| style="text-align:right" | 232
| style="text-align:right" | 216
| style="text-align:right" | 210
|}
</div>
Line 1,205 ⟶ 1,357:
* ¹ Includes net undiscounted claims reserves and unearned premium reserves <sup>p. 38</sup>.
=== P&C | 2026 Simplified Group Nat Cat
<div style="overflow-x:auto">
Line 1,279 ⟶ 1,431:
! style="text-align:left" | Year
! class="col-s" style="text-align:right" | EUR billion
! class="col-s" style="text-align:right" |
|-
| style="text-align:left" | 2025
Line 1,291 ⟶ 1,443:
</div>
* '''Earnings deviation analysis'''
** '''More severe years''' result in a negative deviation in ca. 40% of cases <sup>p. 40</sup>.
** '''Less severe years''' result in a positive deviation in ca. 60% of cases <sup>p. 40</sup>.
* '''Natural catastrophe cost''' is defined as Aggregate Exceedance Probability (AEP) of all natural perils worldwide, net of tax and reinsurance <sup>p. 40</sup>.
* '''Deviation comparison''' is made against a normalized level, which represents costs associated with natural catastrophes expected in an average year (ca. 4.5 points of estimated FY25 GEP, undiscounted and net of reinsurance) <sup>p. 40</sup>.
=== Table of contents ===
* '''Debt and Invested Assets''' <sup>p. 31</sup>
* '''Additional P&C disclosures''' <sup>p. 36</sup>
* '''Additional IFRS17 disclosures''' (active section) <sup>p. 41</sup>
* '''Sustainability''' <sup>p. 44</sup>
=== P&C | Margin analysis ===
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ P&C Underlying Earnings
! style="text-align:left" | Metric
! class="col-s" style="text-align:right" | FY25 (EUR million)
! class="col-s" style="text-align:right" | Change (EUR million)
|-
| style="text-align:left" | '''Underlying
|
|
|-
| style="text-align:left" |
|
|
|-
| style="text-align:left" |
|
|
|-
| style="text-align:left" | '''Underlying
|
|
|-
| style="text-align:left" |
|
|
|}
</div>
Caption: Technical result components (pre-tax, changes versus FY24 at
* '''Undiscounted technical margin''' (current accident year) of EUR 2,778m (+EUR 707m) <sup>p. 42</sup>:
* '''Gross earned premiums''' at EUR 57,656m (+6%) <sup>p. 42</sup>
* '''Undiscounted combined ratio''' (current accident year) at 95.2% (-1.0pt), of which Nat Cats was 3.4% (-0.4pt) <sup>p. 42</sup>
* '''Accident year discounting''' (current accident year) of EUR 2,009m (+EUR 115m) <sup>p. 42</sup>:
* '''Discounting ratio''' (in combined ratio points) at -3.5% (+0.0pt) <sup>p. 42</sup>
* '''Net claims reserves''' (current accident year) at EUR 19.0bn <sup>p. 42</sup>
* '''Reserve duration''' at 4.0 years with a discount rate of 2.8% <sup>p. 42</sup>
* '''Reserve development''' (prior years' PYD) of EUR 622m (-EUR 341m) with a PYD ratio of -1.1% (+0.7pt) <sup>p. 42</sup>
* '''Investment income''' of EUR 3,988m (+EUR 435m) <sup>p. 42</sup>:
* '''Average assets''' (FY25) at EUR 115bn with an asset book yield of 3.5% and reinvestment yield on fixed income assets of 4.3% <sup>p. 42</sup>
* '''Insurance finance expenses''' of -EUR 1,358m (-EUR 235m) <sup>p. 42</sup>:
* '''Reserves at locked-in rate''' (FY24) at EUR 71bn with a liability book yield of 1.9% <sup>p. 42</sup>
* '''Rate increase''' of +25bps: +EUR 0.2bn <sup>p. 42</sup>
* '''Rate decrease''' of -25bps: -EUR 0.2bn <sup>p. 42</sup>
* '''Future finance expenses''' projected for 2026e (pre-tax) at ~ -EUR 1.4bn <sup>p. 42</sup>:
* '''Sensitivity to discount changes''' (+25bps in 2025 current AY discount): ~ -EUR 50m <sup>p. 42</sup>
* '''Sensitivity to discount changes''' (-25bps in 2025 current AY discount): ~ +EUR 50m <sup>p. 42</sup>
=== L&H | Margin analysis ===
* '''L&H Margin Analysis''' includes scope impact <sup>p. 43</sup>.
* '''Short-term Technical Margin''' includes the recapture of Laya <sup>p. 43</sup>.
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+
! style="text-align:left" |
! class="col-s" style="text-align:right" |
! class="col-s" style="text-align:right" | Change
|-
| style="text-align:left" |
| style="text-align:right" |
| style="text-align:right" | +
|-
| style="text-align:left" |
| style="text-align:right" |
| style="text-align:right" | +
|-
| style="text-align:left" |
| style="text-align:right" |
| style="text-align:right" | -
|-
| style="text-align:left" |
| style="text-align:right" |
| style="text-align:right" | +
|-
| style="text-align:left" |
| style="text-align:right" |
| style="text-align:right" |
|-
| style="text-align:left" | Technical experience
| style="text-align:right" | -150
| style="text-align:right" | -58
|}
</div>
Line 1,365 ⟶ 1,546:
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+
! style="text-align:left" |
! class="col-s" style="text-align:right" |
! class="col-s" style="text-align:right" | Change
|-
| style="text-align:left" |
| style="text-align:right" |
| style="text-align:right" | -1
|-
| style="text-align:left" | Insurance Finance Expenses (non-
| style="text-align:right" | -
| style="text-align:right" | -9
|}
</div>
* '''Investment Income details (non-VFA only)''':
** '''FY25 Average Assets''': EUR 98bn <sup>p. 43</sup>
** '''Asset book yield''': 2.5% <sup>p. 43</sup>
** '''FY25 Reinvestment yield¹''': 3.8% <sup>p. 43</sup>
* '''Insurance Finance Expenses details (non-VFA only)''':
** '''FY24 Reserves at locked-in rate''': EUR 62bn <sup>p. 43</sup>
** '''Liability book yield''': 2.5% <sup>p. 43</sup>
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ Underlying Earnings (In Euro million) <sup>p. 43</sup>
! style="text-align:left" |
! class="col-s" style="text-align:right" |
! class="col-s" style="text-align:right" | Change
|-
| style="text-align:left" |
|
| style="text-align:right" | +205
|-
| style="text-align:left" |
|
| style="text-align:right" | 65
|-
| style="text-align:left" | Affiliates, Minority interests & Other
| style="text-align:right" | 72
| style="text-align:right" | -51
|-
| style="text-align:left" | Underlying Earnings
| style="text-align:right" | 3,501
| style="text-align:right" | +219
|}
</div>
* '''
<div style="overflow-x:auto">
Line 1,400 ⟶ 1,600:
|+ Life & Health FY25 CSM Key Sensitivities (in Euro billion) <sup>p. 43</sup>
! style="text-align:left" | Sensitivity
! class="col-s" style="text-align:right" |
|-
| style="text-align:left" |
| style="text-align:right" |
|-
| style="text-align:left" | Interest rates +50bps
Line 1,431 ⟶ 1,631:
</div>
* ¹ Reinvestment yield on fixed income assets <sup>p. 43</sup>.
=== Table of contents ===
Line 1,475 ⟶ 1,637:
=== Expanding AXA's role in society: AXA for Progress Index 1 ===
* '''As a Global Investor''':
** '''Climate transition financing''': Target of EUR 5bn per year in climate transition financing <sup>p. 45</sup>; 2025 Result achieved EUR 6.4bn <sup>p. 45</sup>.
** '''Community resilience financing''': Target of >EUR 500m per year <sup>p. 45</sup>; 2025 Result achieved EUR 1.4bn <sup>p. 45</sup>.
* '''As a Global Insurer''':
** '''Transition underwriting''': Target of EUR 6bn in P&C GWP to support transition underwriting (cumulative 2024-2026) <sup>p. 45</sup>; 2025 Result achieved EUR 4.6bn <sup>p. 45</sup>.
** '''Climate adaptation solutions''': Target of >20,000 climate adaptation solutions & services (cumulative 2024-2026, target revised in 2025) <sup>p. 45</sup>; 2025 Result achieved 19,698 cumulative 2024-2025 <sup>p. 45</sup>.
** '''Inclusive insurance''': Target of >20m inclusive insurance customers by 2026 <sup>p. 45</sup>; 2025 Result achieved 20.6m <sup>p. 45</sup>.
* '''As a Company''':
** '''Climate adaptation training''': Target of >80,000 AXA Group employees trained on climate adaptation by 2026 <sup>p. 45</sup>; 2025 Result achieved 46,420 <sup>p. 45</sup>.
** '''Carbon emissions reduction''': Target to contribute to Net-Zero with -50% by 2030 in absolute carbon emissions and offset of residual emissions <sup>p. 45</sup>; 2025 Result achieved -64% reduction against 2019 <sup>p. 45</sup>.
** '''Employee volunteering''': Target of 50% of AXA Group employees engaged in volunteering activities by 2026 <sup>p. 45</sup>; 2025 Result achieved 56% <sup>p. 45</sup>.
=== Sustainability Performance & Ratings ===
Line 1,520 ⟶ 1,653:
<div style="overflow-x:auto">
{| class="wikitable"
|+ ESG
! style="text-align:left" | Rating
! class="col-
|-
| style="text-align:left" | S&P Global
| class="col-
|-
| style="text-align:left" | MSCI
| class="col-
|-
| style="text-align:left" | CDP
| class="col-
|-
| style="text-align:left" | Morningstar Sustainalytics
| class="col-
|-
| style="text-align:left" | FTSE Russell
| class="col-
|}
</div>
*
* '''FTSE Russell''' 2025 score: 4.3/5 in FTSE4Good Index Series <sup>p. 46</sup>
=== Scope ===
Line 1,569 ⟶ 1,703:
* '''Operating variance''': the variation of the year-end CSM versus the expected at opening due to (i) the differences between realized and expected operational assumptions, (ii) changes in assumptions such as mortality, longevity, lapses and expenses, and (iii) impact of model changes. Operating variance is net of reinsurance <sup>p. 48</sup>
* '''Present value of expected premiums (PVEP)''': the new business volume, equal to the present value at the time of issue of the total premiums expected to be received over the policy term. PVEP is discounted at the reference interest rate and PVEP is Group share <sup>p. 48</sup>
* '''Technical experience''': consists of the impacts on the underlying earnings
* '''Underlying return on in-force''': represents the release of Time Value of Options & Guarantees (TVOG) plus the unwind of CSM at the reference rate plus the underlying financial over-performance <sup>p. 48</sup>
=== February 26, 2026 Thank you Full Year 2025 earnings ===
*
== Abbreviations ==
* '''AA''':
* '''AAA''':
* '''ABS''': Asset-Backed Securities
* '''AEP''': Aggregate Exceedance Probability
* '''AI''': Artificial Intelligence
* '''APAC''': Asia-Pacific
* '''AXA IM''': AXA Investment Managers
* '''AXA XL''': AXA XL (AXA's
* '''AY''': Accident Year
* '''BBA''': Business
* '''CDP''': Carbon Disclosure Project
* '''CLO''': Collateralized Loan Obligation
Line 1,594 ⟶ 1,728:
* '''CSM''': Contractual Service Margin
* '''CY''': Calendar Year
* '''EME''':
* '''EOF''': Eligible Own Funds
* '''EPS''': Earnings Per Share
* '''ESG''': Environmental, Social, and Governance
* '''EU''': European Union
* '''FX''': Foreign Exchange
* '''GAAP''': Generally Accepted Accounting Principles
* '''
* '''
* '''GF GBP''': Grandfathered British Pound
* '''GWP''': Gross Written Premiums
* '''HKD''': Hong Kong Dollar
Line 1,619 ⟶ 1,752:
* '''NB CSM''': New Business Contractual Service Margin
* '''NBV''': New Business Value
* '''NHG''': Nationale Hypotheek Garantie
* '''NPS''': Net Promoter Score
* '''OCI''': Other Comprehensive Income
Line 1,625 ⟶ 1,758:
* '''PE''': Private Equity
* '''PVEP''': Present Value of Expected Profits
* '''PYD''': Prior
* '''RCG''':
* '''ROE''': Return on Equity
* '''SCR''': Solvency Capital Requirement
* '''SHE''': Shareholders' Equity
* '''SME''': Small and Medium-sized Enterprises
* '''TVOG''': Time Value of Options
* '''UEPS''': Underlying Earnings Per Share
* '''UK''': United Kingdom
* '''US''': United States
* '''USD''': United States Dollar
* '''VAT''': Value Added Tax
* '''VFA''': Variable Fee Approach
| |||